West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

West Pharmaceutical Services (NYSE:WST) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $199.40 on Friday. The business has a 50-day moving average price of $330.01 and a two-hundred day moving average price of $314.33. West Pharmaceutical Services has a 1-year low of $197.01 and a 1-year high of $408.88. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. The company has a market cap of $14.44 billion, a P/E ratio of 29.58, a PEG ratio of 19.31 and a beta of 1.01.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 dividend on an annualized basis and a yield of 0.42%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.46%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on WST shares. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. Citigroup began coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price on the stock. Wolfe Research began coverage on shares of West Pharmaceutical Services in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a research note on Friday. Finally, StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and an average target price of $348.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.